Showing all 2 results
Tenofovir, Lamivudine & Dolutegravir Tablets
FreeProduct Composition & Strength
We supply this product as a highly advanced Film-Coated Tablet, packed strictly in heavy-gauge HDPE bottles with integrated silica gel desiccants. This packaging is absolutely non-negotiable, as Tenofovir is highly susceptible to hydrolytic degradation in humid environments.
Active Ingredient Strength Primary Clinical Function Tenofovir Disoproxil Fumarate (TDF) INN/Ph.Eur. 300 mg Potent Nucleotide Reverse Transcriptase Inhibitor (NRTI). Lamivudine (3TC) INN/Ph.Eur. 300 mg Synergistic Nucleoside Reverse Transcriptase Inhibitor (NRTI). Dolutegravir (DTG) INN/Ph.Eur. 50 mg Advanced Integrase Strand Transfer Inhibitor (INSTI). Excipients Microcrystalline Cellulose / Croscarmellose Sodium / Sodium Staryl Fumarate Diluent / Superdisintegrant / Lubricant (Engineered for uniform FDC dissolution) Varenicline Tablets
FreeProduct Composition & Strength
We supply this product as a Film-Coated Tablet, packed in highly secure, moisture-resistant Alu-Alu blister strips. We specifically offer the globally mandated “Titration Starter Packs” to ensure patient compliance during the critical first two weeks of therapy.
Active Ingredient Strength Primary Clinical Use Varenicline Tartrate INN/USP 0.5 mg Mandatory dose-titration initiation (Days 1 through 7 of the quit attempt). Varenicline Tartrate INN/USP 1 mg Standard Adult Maintenance Dose (Day 8 through Week 12 or 24). Excipients Microcrystalline Cellulose / Anhydrous Dibasic Calcium Phosphate / Croscarmellose Sodium Diluent / Superdisintegrant (Ensures rapid, uniform gastric dispersion)
